November 21st 2024
Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.
November 19th 2024
The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.
November 16th 2024
A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.
October 29th 2024
Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.
October 13th 2024
A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.